Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07301333
PHASE1

A Study of Single and Multiple Doses of HRS-6257 in Healthy Subjects

Sponsor: Shanghai Hengrui Pharmaceutical Co., Ltd.

View on ClinicalTrials.gov

Summary

This is a phase I, randomised, single-blind placebo-controlled, 2-part study to assess the safety, tolerability, pharmacokinetics, pharmacodynamics and food effect of single and multiple oral doses of HRS-6257 in healthy volunteers.

Official title: A Phase 1 Study To Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and the Effect of Food on the Bioavailability of HRS-6257 in Healthy Subjects

Key Details

Gender

All

Age Range

18 Years - 55 Years

Study Type

INTERVENTIONAL

Enrollment

80

Start Date

2025-12-30

Completion Date

2026-05

Last Updated

2026-04-07

Healthy Volunteers

Yes

Conditions

Interventions

DRUG

HRS-6257

HRS-6257

DRUG

placebo

placebo

Locations (1)

Third Xiangya Hospital of Central South University

Changsha, Hunan, China